COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet Lond Engl. 2022 Mar 10;S0140-6736(21)02796-3.

Honardoost M. Janani L. Aghili R. Emami Z. Khamseh M.E.

The Association between Presence of Comorbidities and COVID-19 Severity: A Systematic Review and Meta-Analysis.

Cerebrovasc Dis Basel Switz. 50: 132-140Hobohm L. Sagoschen I. Barco S. Schmidtmann I. Espinola-Klein C. Konstantinides S. et al.

Trends and Risk Factors of In-Hospital Mortality of Patients with COVID-19 in Germany: Results of a Large Nationwide Inpatient Sample.

Viruses. 14: 275Chaturvedi A. Kanwar M. Chandrika P. Thenappan T. Raina A. Benza R.L.

National trends and inpatient outcomes of pulmonary arterial hypertension related hospitalizations - Analysis of the National Inpatient Sample Database.

Int J Cardiol. 319: 131-138

Harder EM, Small AM, Fares WH. Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. Respir Med. 2020 Jan;161:105850.

Horn EM, Chakinala M, Oudiz R, Joseloff E, Rosenzweig EB. Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19? Pulm Circ. 2020 Apr;10(2):204589402092279.

Scuri P, Iacovoni A, Abete R, Cereda A, Grosu A, Senni M. An unexpected recovery of patients with pulmonary arterial hypertension and SARS-CoV-2 pneumonia: a case series. Pulm Circ. 2020 Jul;10(3):204589402095658.

Nuche J. Pérez-Olivares C. Segura de la Cal T. Jiménez López-Guarch C. Arribas Ynsaurriaga F. Escribano Subías P.

Clinical course of COVID-19 in pulmonary arterial hypertension patients.

Rev Esp Cardiol Engl Ed. 73: 775-778Montani D. Certain M.C. Weatherald J. Jaïs X. Bulifon S. Noel-Savina E. et al.

COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study.

Am J Respir Crit Care Med. Belge C. Quarck R. Godinas L. Montani D. Escribano Subias P. Vachiéry J.L. et al.

COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey.

ERJ Open Res. 6: 00520-2020Lee J.D. Burger C.D. Delossantos G.B. Grinnan D. Ralph D.D. Rayner S.G. et al.

A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care.

Ann Am Thorac Soc. 17: 1576-1582Farmakis I.T. Karyofyllis P. Frantzeskaki F. Demerouti E. Anthi A. Arvanitaki A. et al.

Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE).

Hell J Cardiol HJC Hell Kardiologike Epitheorese. 64: 93-96

Badagliacca R, Papa S, D’Alto M, Ghio S, Agostoni P, Ameri P, et al. The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner? Eur Respir J. 2022 Mar 17;2102276.

Hewitt J. Carter B. Vilches-Moraga A. Quinn T.J. Braude P. Verduri A. et al.

The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study.

Lancet Public Health. 5: e444-e451

Therapeutics and COVID-19: living guideline [Internet]. [cited 2021 Feb 25]. Available from: https://www.who.int/publications/i/item/therapeutics-and-covid-19-living-guideline

Hoeper MM, Benza RL, Corris P, de Perrot M, Fadel E, Keogh AM, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2019 Jan;53(1):1801906.

Puk O, Nowacka A, Smulewicz K, Mocna K, Bursiewicz W, Kęsy N, et al. Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review. Biomed Pharmacother Biomedecine Pharmacother. 2022 Feb;146:112592.

Moezinia C.J. Ji-Xu A. Azari A. Horlick S. Denton C. Stratton R.

Iloprost for COVID-19-related vasculopathy.

Lancet Rheumatol. 2: e582-e583Sonti R. Pike C.W. Cobb N.

Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19.

J Intensive Care Med. 36: 327-333

Matthews L, Baker L, Ferrari M, Sanchez W, Pappachan J, Grocott MP, et al. Compassionate use of Pulmonary Vasodilators in Acute Severe Hypoxic Respiratory Failure due to COVID-19. J Intensive Care Med. 2022 Apr 4;8850666221086521.

Castiglione L, Droppa M. Pulmonary Hypertension and COVID-19. Hamostaseologie. 2021 Dec 21;

McFadyen C, Garfield B, Mancio J, Ridge CA, Semple T, Keeling A, et al. Use of sildenafil in patients with severe COVID-19 pneumonitis. Br J Anaesth. 2022 Apr 15;S0007-0912(22)00186-6.

Wieteska-Miłek M. Szmit S. Florczyk M. Kuśmierczyk-Droszcz B. Ryczek R. Kurzyna M.

COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination.

Vaccines. 9: 1395Galiè N. Humbert M. Vachiery J.L. Gibbs S. Lang I. Torbicki A. et al.

ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Eur Heart J. 37: 67-119Wesley Milks M. Sahay S. Benza R.L. Farber H.W.

Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review.

J Heart Lung Transplant. 40: 172-182

Ryan JJ, Melendres-Groves L, Zamanian RT, Oudiz RJ, Chakinala M, Rosenzweig EB, et al. Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic. Pulm Circ. 2020 Apr;10(2):204589402092015.

Tamura Y, Takeyasu R, Furukawa A, Takada H, Takechi M, Taniguchi H, et al. How COVID-19 Affected the Introduction of Telemedicine and Patient Reported Outcomes Among Patients With Pulmonary Hypertension ― A Report From a Referral Center in Japan ―. Circ Rep. 2(9):526–530.

Wieteska-Miłek M. Szmit S. Florczyk M. Kuśmierczyk-Droszcz B. Ryczek R. Dzienisiewicz M. et al.

Fear of COVID-19, Anxiety and Depression in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension during the Pandemic.

J Clin Med. 10: 4195Godinas L. Iyer K. Meszaros G. Quarck R. Escribano-Subias P. Vonk Noordegraaf A. et al.

PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic.

Orphanet J Rare Dis. 16: 196Halawa S. Pullamsetti S.S. Bangham C.R.M. Stenmark K.R. Dorfmüller P. Frid M.G. et al.

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective.

Nat Rev Cardiol. 19: 314-331Nalbandian A. Sehgal K. Gupta A. Madhavan M.V. McGroder C. Stevens J.S. et al.

Post-acute COVID-19 syndrome.

Nat Med. 27: 601-615

Suzuki YJ, Nikolaienko SI, Shults NV, Gychka SG. COVID-19 patients may become predisposed to pulmonary arterial hypertension. Med Hypotheses. 2021 Feb;147:110483.

Pagnesi M. Baldetti L. Beneduce A. Calvo F. Gramegna M. Pazzanese V. et al.

Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19.

Heart Br Card Soc. 106: 1324-1331Norderfeldt J. Liliequist A. Frostell C. Adding C. Agvald P. Eriksson M. et al.

Acute pulmonary hypertension and short-term outcomes in severe Covid-19 patients needing intensive care.

Acta Anaesthesiol Scand. 65: 761-769Caravita S. Baratto C. Di Marco F. Calabrese A. Balestrieri G. Russo F. et al.

Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization.

Eur J Heart Fail. 22: 2228-2237Xie Y. Xu E. Bowe B. Al-Aly Z.

Long-term cardiovascular outcomes of COVID-19.

Nat Med. 28: 583-590

Katsoularis I, Fonseca-Rodríguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022 Apr 6;377:e069590.

Bikdeli B. Madhavan M.V. Jimenez D. Chuich T. Dreyfus I. Driggin E. et al.

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.

J Am Coll Cardiol. 75: 2950-2973Sulica R. Cefali F. Motschwiller C. Fenton R. Barroso A. Sterman D.

COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City.

Diagnostics. 11: 128